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298 The Journal of Thoracic and CardioObjective: DNA methyltransferase (DNMT)1, DNMT3b, or both, facilitate malignant
transformation through chromatin remodeling mechanisms. The present study was
undertaken to examine the effects of antisense-mediated inhibition of DNMT expression
in cultured thoracic malignancies.
Methods: CALU-6 and A549 lung cancer, SKGT5 and BIC esophageal adenocarci-
noma, and H2373 and H2052 malignant pleural mesothelioma (MPM) cells, as well as
normal human bronchial epithelial (NHBE) cells, were transfected with phosphorothio-
ate-modified antisense oligos targeting DNMT1, DNMT3b, or both, or mismatch oligos.
Quantitative reverse transcription–polymerase chain reaction, Western blotting, trypan
blue exclusion, and ApoBrdU techniques were used to evaluate DNMT expression,
proliferation, and apoptosis after antisense oligo transfections. Gene expression profiles
were assessed by using long-oligo array techniques.
Results: Antisense oligos mediated specific and dose-dependent depletion of DNMT1
and DNMT3b, resulting in pronounced inhibition of proliferation of all thoracic cancer
lines, but not NHBE cells. Depletion of DNMT1 or DNMT3b coincided with dramatic,
caspase-dependent, p53-independent apoptosis in 4 of the 6 thoracic cancer lines. The
antiproliferative effects of the antisense oligos were not attributable to induction of
RASSF1A, p16, or p21 tumor suppressor genes, and did not coincide with demethyl-
ation of genes encoding cancer-testis antigens. DNA methyltransferase knockdown
mediated induction of numerous genes regulating response to genotoxic stress. Gene
expression profiles after DNMT1, DNMT3b, or combined DNMT1/3b depletion were
remarkably similar, yet distinctly different from expression profiles mediated by 5 aza
2= deoxycytidine.
Conclusions: Antisense oligos targeting DNMT1 and DNMT3b induce genomic stress,
and mediate potent growth inhibition in lung and esophageal cancer and MPM cells.
These findings support further evaluation of DNMT knockdown strategies for cancer
therapy.
Dynamic patterns of gene expression during embryonic development andcellular homeostasis, as well as stable repression of gene expression asso-ciated with X chromosome inactivation and imprinting, are mediated by
epigenetic mechanisms involving DNA methylation in conjunction with acetylation,
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TSphosphorylation, and methylation of core histone pro-
teins.1,2 In mammalian cells methylation of DNA occurs
exclusively at the 5= position of cytosine in the context of
CG dinucleotides.3 Methylation of cytosines within CpG
islands of promoter and proximal coding regions facilitates
recruitment of methyl-binding proteins, such as MeCP2 and
MBD2, as well as histone deacetylases (HDACs), which
inhibit gene expression through complex mechanisms that
render promoters inaccessible to the transcription machin-
ery.4 Reversible posttranslational modifications of core hi-
stone proteins (histones H2a, H2b, H3, and H4) form a
histone code that determines the specificity of DNA-protein
and protein-protein interactions within the nucleosome, thus
modulating activation status of chromatin.5 Recent studies
indicate that DNA methylation is mechanistically linked to
the histone code6-8 and that DNA methylation is the pre-
dominant epigenetic mechanism regulating gene expression
in healthy, as well as cancer, cells.9
DNA methylation is mediated by opposing actions of
DNA methyltransferases (DNMTs) and DNA demethy-
lases.10 To date, 4 DNMTs have been identified (DNMT1,
DNMT2, DNMT3a, and DNMT3b), all of which mediate
transfer of a methyl group from S-adenosyl methionine to
the 5= position of cytosine.3 Recent studies in which indi-
vidual DNMTs have been knocked out in cultured cells
have revealed unique functions and considerable overlap-
ping activities of these isozymes. In normal somatic cells
DNMT1 is the predominant methyltransferase, functioning
primarily to maintain DNA methylation patterns after DNA
replication. DNMT3a and DNMT3b are also expressed in
healthy tissues, albeit at levels considerably lower than
DNMT1, and function primarily in de novo methylation.
DNMT2 appears to have minimal activity, and its role in
regulating DNA methylation in mammalian cells is pres-
ently unknown. DNMT1, DNMT3a, or DNMT3b knockout
mice die in utero or shortly after birth, indicating that
despite redundant functions, all of these DNMTs are essen-
tial for normal development.10,11
Aberrant DNMT expression-activity facilitates malig-
nant transformation in part by mediating site-specific pro-
Abbreviations and Acronyms
ASO  antisense oligo
DAC  5 aza 2= deoxycytidine
DNMT  DNA methyltransferase
HDAC  histone deacetylase
MM mismatch
MPM malignant pleural mesothelioma
NHBE cell Normal human bronchial epithelial cell
RT-PCR  reverse transcription–polymerase chain
reactionmoter methylation of tumor suppressor genes, such as p16,
The Journal of ThoraciFHIT, and RASSF1A. Robertson and colleagues12 observed
a 3- to 7-fold increase in DNMT1, DNMT3a, and DNMT3b
expression in primary tumor specimens (including lung
carcinomas) relative to adjacent normal tissues. More re-
cently, Yakushiji and associates13 observed overexpression of
DNMT1, DNMT3a, and DNMT3b in 72%, 56%, and 64%,
respectively, of oropharyngeal cancers relative to corre-
sponding normal epithelia, suggesting that increased
DNMT expression might be a common theme of tobacco-
induced aerodigestive tract carcinogenesis. Additional stud-
ies have demonstrated that DNMT1 overexpression induces
DNA methylation and malignant transformation of NIH-
3T3 cells,14 and that increased DNMT activity in type II
pneumocytes coincides with progression to malignancy in
mice exposed to tobacco carcinogens.15 Furthermore,
DNMT3b enhances malignant transformation of SV40 T
antigen–transformed human bronchial epithelial cells ex-
pressing activated ras and telomerase16 and cooperates with
DNMT1 to silence tumor suppressor genes in cancer cells.17
These observations, as well as data reported by Robert and
coworkers18 and Beaulieu and colleagues19 demonstrating
that specific inhibition of DNMT1 or DNMT3b (but not
DNMT3a) expression promotes growth arrest in cancer
cells attest to the relevance of DNMT expression-activity
during malignant transformation. The present study was
undertaken to examine the effects of antisense-mediated
inhibition of DNMT expression in cultured thoracic malig-
nancies as a prelude to possible evaluation of DNMT
knockdown in patients with these neoplasms.
Materials and Methods
Cell Lines
A549 and CALU-6 NSCLC cells, SKGT-5 and BIC esophageal
adenocarcinoma cells, and H2373 and H2052 MPM cells were
available in our laboratory. All cancer lines were maintained in
RPMI supplemented with 10% fetal calf serum and antibiotics
(herein referred to as normal media). Normal human bronchial
epithelial (NHBE) cells were purchased from Clonetics and cul-
tured per the vendor’s recommendations. All cell lines were con-
firmed to be free of mycoplasma contamination.
Oligo Transfections
Cancer cells and NHBE cells were seeded into 10-cm dishes at
concentrations predetermined to yield 40% to 50% confluency
within 24 hours. The following day, media was aspirated, and cells
were transfected with 2=-O-methylphosphorothioate–modified an-
tisense oligos (ASOs) targeting DNMT1, DNMT3B, or both or
mismatch (MM) oligo sequences in Opti-MEM (Gibco, Inc) in the
presence of 2.5 g/mL lipofectin at 37°C  4 hours, as described
by Beaulieu and colleagues.19 Thereafter, transfection medium
was aspirated and replaced with normal medium. This process was
repeated every 24 hours for 2 additional transfections. Additional
cells were treated with lipofectin alone to rule out carrier toxicity.
All transfections were performed in triplicate. Seventy-two hours
after commencement of the initial transfections, cells were har-
c and Cardiovascular Surgery ● Volume 131, Number 2 299
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using standard trypan blue exclusion techniques and protocols-
reagents contained in the APO-BrdU Kit (BD PharMingen), re-
spectively, as well as isolation of RNA and protein for assays
described below, by using triplicate samples for all respective
analyses.
Real-Time Quantitative Reverse
Transcription–Polymerase Chain Reaction
Total RNA was isolated from cell lines by using the Stratagene
Absolutely RNA RT-PCR Miniprep Kit. Synthesis of cDNA was
performed with 1 g of total RNA by using the Reverse Tran-
scription System (Promega) and oligo (dT)15 primers. Real-time
quantitative reverse transcription–polymerase chain reaction (RT-
PCR) was performed as previously described20 using an ABI
Prism 7700 Sequence Detection System (Perkin Elmer). Primer-
probe sequences are listed in Appendix E1. Samples were quan-
titated by dividing the copy number of the respective gene of
interest by that of -actin.
Caspase Inhibition Assay
A549 cells were transfected with DNMT ASOs or MM oligos as
described above. After each 4-hour transfection, the cells were
washed with Hanks’ balanced salt solution and incubated in nor-
mal media containing 80 mol/L of the pancaspase inhibitor
Z-VAD-FMK or the specific caspase 3 inhibitor Z-DEVD-FMK
(R&D Systems). At the 72-hour time point, cells were harvested,
and apoptosis was evaluated by using ApoBrdU techniques de-
scribed above.
Long-oligo Array
Microarray techniques were used to examine gene expression pro-
files of A549 cells exposed to normal media; lipofectin; ASOs for
DNMT1, DNMT3b, or both; MM oligos; or the DNA-demethylating
agent 5 aza 2= deoxycytidine (DAC). Techniques for hybridization
TABLE 1. Quantitative RT-PCR analysis of DNMT1 and DN
([copy no./-actin]  104)
CALU-6
DNMT1 quantitative RT-PCR
NM 31,869
Lipofectin 33,121 1
DNMT1 ASO 75 nmol/L 11,799
DNMT3b ASO 75 nmol/L 30,217
DNMT1/DNMT3b ASO 75/75 nmol/L 11,901
Mismatch 34,568 1
DNMT3b quantitative RT-PCR
NM 26,374 1
Lipofectin 25,454 1
DNMT1 ASO 75 nmol/L 17,767 1
DNMT3b ASO 75 nmol/L 759
DNMT1/3b ASO 75/75 nmol/L 928
Mismatch 24,521 4
RT-PCR, Reverse transcription–polymerase chain reaction; DNMT, DNA mand analysis of the arrays are discussed in Appendix E2.
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Preliminary experiments were performed to optimize trans-
fection conditions and define appropriate time points for
reproducible molecular analysis of oligo-transfected cells.
Real-time quantitative RT-PCR analysis demonstrated con-
siderable variation in basal expression of DNMT1, as well
as DNMT3b, in cultured cancer cells, which did not
appear to coincide with histology or p53 expression status
(Table 1). Subsequent studies revealed that ASOs targeting
DNMT1 and DNMT3b mediated pronounced and specific
dose-dependent reduction of DNMT1 and DNMT3b tran-
scription in all of the cancer lines (data pertaining to 75
nmol/L oligo transfections are depicted in Table 1). In
general, the DNMT3b ASO appeared to more efficiently
inhibit target transcription compared with the ASO recog-
nizing DNMT1. Inhibition of DNMT transcription by the
ASOs coincided with depletion of DNMT protein levels in
cancer cells (representative results pertaining to DNMT1
knockdown in A549 cells are shown in Figure E1).
Additional experiments were performed to ascertain
the growth-inhibitory effects of the ASOs in cultured
cells. In general, the individual ASOs mediated dose-
dependent growth inhibition within 72 hours after initi-
ation of the transfection experiments (Figure 1, A ). The
effects of combined DNMT1/DNMT3b ASO transfec-
tions were somewhat variable, ranging from a rather limited
combination effect, as seen in BIC esophageal adenocarci-
noma cells, to an apparent supra-additive effect noted in
A549 lung cancer cells. Overall, the growth-inhibitory ef-
fects of the DNMT ASOs alone or in combination appeared
to coincide with their ability to diminish DNMT expression
in cancer cells (Figure 1, A, and Table 1). No growth
b expression in cancer cells after ASO treatment
BIC SKGT5 H2373 H2052
3277 1850 11,766 7952
5584 2001 11,056 11,270
685 817 4220 1735
4327 2095 10,865 10,401
1272 1222 5042 1999
4434 2290 9885 11,938
8165 2761 2802 6203
12,727 4339 2304 6503
10,998 3053 1891 4825
1278 696 394 1210
1879 970 556 1142
13,447 3876 1894 6284
transferase; ASO, antisense oligos; NM, normal media.MT3
A549
8226
1,866
863
6753
3076
1,735
3,645
8,273
0,378
1483
1762
6,211inhibition was observed in cancer cells transfected with
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ingly, DNMT ASO transfections had minimal inhibitory
effects on proliferating NHBE cells (Figure 1, B), which
exhibited DNMT1 and DNMT3b mRNA levels 2- to 12-
fold lower than those seen in cultured cancer cells (data not
shown).
Additional studies were performed to further define the
mechanisms by which the DNMT ASOs mediate growth
arrest in cultured cancer cells. Whereas the combination of
DNMT1 and DNMT3b ASOs appeared to have relatively
The Journal of Thoracimodest effects when assessed by trypan blue exclusion
techniques, parallel terminal deoxynucleotidyl transferase
experiments with the same cells revealed that knockdown of
DNMT3b markedly augmented apoptosis in CALU-6 (p53
null) and A549 (p53 wt) lung cancer cells, as well as
SKGT5 esophageal adenocarcinoma cells (p53 mt) medi-
ated by the DNMT1 ASO (Figure 2). The combination
effect was less readily discernable in H2373 MPM (p53 wt)
cells because of their exquisite sensitivity to the DNMT3b
Figure 1. Trypan blue exclusion anal-
ysis of proliferation of CALU-6, A549,
BIC, SKGT5, H2373, and H2052 (A) and
normal human bronchial epithelial
cells (NHBE; B) after antisense oligo
(ASO) transfection. Day 0 counts rep-
resent the number of viable cells im-
mediately before initial exposure to
DNA methyltransferase (DNMT) ASOs,
mismatch (MM) oligos, or lipofectin.
Day 3 counts represent cell numbers at
the 72-hour time point for normal me-
dia (NM), lipofectin (lipofectin alone),
MM oligos, DNMT1 ASOs (25, 50, and
75 nmol/L), DNMT3b ASOs (25, 50, and
75 nmol/L), and combination DNMT1/
DNMT3b ASOs (25, 50, 75 nmol/L).
NHBE cells were exposed only to 75
nmol/L DNMT 1 or DNMT 3b.oligo. Interestingly, 2 cell lines (BIC esophageal adenocar-
c and Cardiovascular Surgery ● Volume 131, Number 2 301
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apoptosis after exposure to the ASOs, despite comparable
knockdown of target transcripts. Additional experiments
revealed that apoptosis mediated by DNMT1 or DNMT3b
ASOs was partially abrogated by the pancaspase inhibitor
Z-VAD, as well as the specific caspase 3 inhibitor DEVD
(Figure 3). Collectively, these data indicated that apoptosis
mediated by DNMT1 knockdown, DNMT3b knockdown,
or both, was mediated through p53-independent, caspase-
dependent mechanisms.
Additional real-time quantitative RT-PCR experiments
were performed to ascertain whether growth inhibition and
apoptosis coincided with induction of tumor suppressor
genes or genomic demethylation in cancer cells after
DNMT knockdown. Representative results are depicted in
Table 2. Overall, knockdown of DNMT1, DNMT3b, or
Figure 2. ApoBrdU analysis of CALU-6 (A), A549 (B), BIC
lipofectin alone, mismatch oligonucleotides, or DNA
oligos (ASOs; 25 or 75 nmol/L). The percentage of
corresponding box. SKGT5 cells exhibited a pattern of a
whereas results pertaining to H2052 cells were similacombined DNMT1/DNMT3b depletion resulted in rela-
302 The Journal of Thoracic and Cardiovascular Surgery ● Febrtively modest effects regarding RASSF1A, p16, p21, and
TFPI-2 tumor suppressor gene expression in cancer cells,
irrespective of their propensity to undergo apoptosis after
ASO exposure. Furthermore, no consistent derepression of
NY-ESO-1 or MAGE-3 cancer testis antigens was ob-
served. In light of the fact that the genes encoding these
tumor suppressors and cancer testis antigens are robustly
induced in cancer cells by the DNA-demethylating agent
DAC,20-22 these data strongly suggested that the ASOs
targeting DNMT1 and DNMT3b mediated their growth-
inhibitory effects through mechanisms more subtle than
restoration of tumor suppressor gene expression or global
DNA demethylation. Long-oligo array techniques were
used to evaluate gene expression profiles in A549 lung
cancer cells after DNMT knockdown to further examine this
issue. This analysis revealed that depletion of DNMT ex-
nd H2373 (D) cell lines exposed to normal media (NM),
yltransferase (DNMT) 1, DNMT3b, or both antisense
ptotic cells for each exposure is indicated in the
osis similar to that observed for CALU-6 and A549 cells,
those observed for BIC cells (data not shown).(C), a
meth
apo
popt
r topression resulted in a dramatic induction of a variety of
uary 2006
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stress through p53-dependent, as well as p53-independent,
mechanisms (a partial list of these genes is included in
Table 3). Interestingly, the patterns of genes induced by the
DNMT1 and DNMT3b ASOs were remarkably similar, and
there was little evidence of a cumulative effect of DNMT1/
DNMT3b knockdown in terms of the genes that were most
profoundly induced under these treatment conditions. Fur-
thermore, none of the genes induced by ASO transfections
were upregulated to a significant extent after 72-hour expo-
sure to DAC at maximal concentrations achievable in clin-
ical settings (0.1 mol/L).11
Discussion
The emerging relationships between chromatin structure,
Figure 3. ApoBrdU analysis of apoptosis in A549 cells exposed to
DNA methyltransferase (DNMT) 1 antisense oligo (ASO) alone,
DNMT1 ASO plus Z-VAD, or DNMT1 ASO plus DEVD (A) or A549
cells exposed to DNMT3b ASO alone, DNMT3b ASO plus Z-VAD,
or DNMT3b ASO plus DEVD (B). Cells were also treated with
control exposure to normal media (NM), lipofectin alone, and
mismatch (MM) oligos. The x axis indicates the percentage of
apoptotic cells. Both caspase inhibitors partially abrogated the
apoptotic effects of DNMT1 and DNMT3b ASOs.gene regulation, and malignant transformation provide a
The Journal of Thoracicompelling rationale for evaluation of DNMT inhibitors for
the treatment and prevention of cancer.11,23 Clinical studies
conducted recently in the Thoracic Oncology Section, Sur-
gery Branch, National Cancer Institute, indicate that when
administered via 72-hour continuous intravenous infusion,
DAC mediates induction of tumor suppressor and cancer-
testis gene expression in primary thoracic malignancies.
Despite these encouraging results, dose-limiting myelosup-
pression and drug instability in vivo (half-life, approxi-
mately 5 minutes) limit chronic administration of DAC in
patients with thoracic malignancies, or individuals at high
risk for development of these neoplasms.11
In light of the cooperativity of DNMT1 and DNMT3b
regarding inhibition of tumor suppressor gene expression17
and the requirement of DNMT3b for cancer cell survival,19
we sought to ascertain the potential utility of ASO-mediated
depletion of these DNMTs for the treatment of thoracic
malignancies. At concentrations 200-fold less than those
achieved in phase I studies examining 2-hour DNMT1 ASO
infusions in patients with cancer,24 DNMT1 and DNMT3b
ASOs mediated potent and dose-related depletion of target
transcripts, markedly inhibiting proliferation of all thoracic
cancer lines. Interestingly, 2 cancer lines (BIC and H2052)
appeared refractory to the proapoptotic effects of DNMT
ASOs, despite depletion of target transcripts comparable
with cell lines that readily underwent apoptosis after ASO
transfection. Although the basis for this has not been eluci-
dated, these findings might be related in part to the kinetics
of DNMT knockdown, differential modulation of multipro-
tein chromatin-remodeling complexes, and the status of
apoptotic pathways in these cancer cells. Of note, the
DNMT ASOs mediated minimal toxicity in proliferating
NHBE cells. Although these observations could be attrib-
utable, at least in part, to relative transfection efficiencies,
the data suggest that cancer cells are more susceptible to
antisense-mediated inhibition of DNMTs; these findings are
consistent with previously published data from our labora-
tory indicating that DNA-demethylating agents and HDAC
inhibitors mediate apoptosis preferentially in cancer
cells.22,25
Several studies have been conducted to examine mech-
anisms by which DNMT knockdown inhibits cancer cell
proliferation in cancer cells. Beauleiu and colleagues19 ob-
served that apoptosis mediated by DNMT knockdown in
A549 lung cancer cells coincided with inhibition of prolif-
erating cell nuclear antigen expression and induction of
RASSF1A and p21, as well as caspases 9 and 10; in our
study we did not observe significant induction of these
genes in these cells. Robert and coworkers18 reported that
DNMT1 knockdown, but not depletion of DNMT3b or
DNMT3a, markedly augmented the ability of DAC to
reactivate silenced tumor suppressor genes in cancer
cells. More recently, Milutinovic and associates26 ob-
c and Cardiovascular Surgery ● Volume 131, Number 2 303
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cell-cycle arrest and genotoxic stress in A549 cells, which
was due specifically to depletion of DNMT1, rather than
global DNA demethylation. Interestingly, these effects were
not noted in cells treated with DAC, which inhibits DNA
demethylation by covalently trapping DNMTs at the repli-
cation fork, without inhibiting their transcription.27,28 Su-
zuki and colleagues29 reported that short interfering RNA
(siRNA)–mediated knockdown of DNMT1 induced expres-
sion of a variety of tumor suppressor genes, including p16,
RASSF1A, and E-cadherin, in H1299 lung cancer cells.
Modulation of gene expression was transient because genes
that had been induced were repressed within 17 days after
exposure to the siRNA, indicating a selective pressure to
silence these genes in cancer cells. Collectively, these data
TABLE 3. Long-oligo array analysis of gene expression in
induction relative to normal media)
Gene Mismatch DNMT1
GADD45A 1 12
TNFAIP3 1 11
SESN2 1 9
EGR1 1 6
EPLIN 1 5
GADD45B 1 5
AXUD1 1 5
HISTONE 2, Hbe 1 5
TABLE 2. Quantitative RT-PCR analysis of tumor suppresso
treatment ([copy no./-actin]  104)
RASSF1A p16
A549
NM 6 0
DNMT1 ASO 75 nmol/L 6 0
DNMT3 ASO 75 nmol/L 7 0
DNMT1/3 ASO 75/75 nmol/L 11 0
MM 75/75 nmol/L 6 0
CALU-6
NM 102,836 0
DNMT1 ASO 75 nmol/L 48,469 7
DNMT3 ASO 75 nmol/L 49,566 2
DNMT1/3 ASO 75/75 nmol/L 39,028 6
MM 75/75 nmol/L 97,657 1
BIC
NM 11,466 0
DNMT1 ASO 75 nmol/L 8745 1
DNMT3 ASO 75 nmol/L 14,984 1
DNMT1/3 ASO 75/75 nmol/L 14,077 1
MM 75/75 nmol/L 10,687 0
RT-PCR, Reverse transcription–polymerase chain reaction; ASO, antisensASO, Antisense oligos; DNMT, DNA methyltransferase; DAC, 5 aza 2= deoxycyt
304 The Journal of Thoracic and Cardiovascular Surgery ● Febrindicate that the antiproliferative effects of DNMT inhibi-
tors in cancer cells are contingent on the mechanisms by
which these agents abrogate DNMT expression-activity, as
well as the specificity, extent, and duration of DNMT
depletion.
Results of our studies clearly indicate that DNMT1 and
DNMT3b contribute to the malignant phenotype of thoracic
malignancies. Interestingly, our data suggest that apoptosis
mediated by DNMT knockdown is not readily attributable
to genomic DNA demethylation, as evidenced by the lack of
induction of tumor suppressor genes or derepression of
cancer testis genes, which are regulated through DNA meth-
ylation mechanisms.11,23 Instead, DNMT knockdown me-
diates a genomic stress response, which appears remarkably
similar, irrespective of whether DNMT1, DNMT3b, or both
lung cancer cells after ASO treatment (approximate fold
DNMT3b DNMT1/DNMT3b DAC 0.1 mol/L
18 19 2
9 14 1
8 14 1
24 26 1
5 6 1
6 6 1
8 7 1
10 10 1
d cancer-testis gene expression in cancer cells after ASO
p21 TFPI-2 NY-ESO-1 MAGE-3
4692 273,290 0 1214
21,889 459,952 1 1237
39,197 429,845 1 1051
23,359 399,188 1 1151
6632 268,718 1 1482
278 8 1 3011
458 9 2 4828
270 12 2 5285
253 8 2 4076
190 8 0 3921
288 1 35 1
375 1 65 2
664 1 29 2
644 2 35 1
394 1 33 1
os; NM, normal media; DNMT, DNA methyltransferase; MM, mismatch.A549r an
e oligidine.
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the notion that knockdown of DNMTs initially (and perhaps
primarily) disrupts cellular processes other than DNA meth-
ylation, resulting in growth arrest and apoptosis in cancer
cells.30 For example, DNMTs participate in multiprotein
complexes involving methyl-binding proteins, HDACs,
p21, and PCNA, which regulate chromatin structure and
cell-cycle progression.10,11 As such, depletion of DNMTs
might alter the stability of a variety of critical protein
complexes, thereby inducing lethal genotoxic stress. The
fact that DAC did not induce similar genotoxic stress is
consistent with the notion that depletion of DNMT protein
levels rather than covalent trapping of these methyltrans-
ferases onto DNA directly contributes to the cytotoxicity of
DNMT ASOs. The mechanisms by which DNMT depletion
mediates growth arrest in cancer cells are a focus of ongoing
investigation in our laboratory.
Our current study is the first comprehensive analysis of com-
bined DNMT depletion in a broad panel of well-characterized
lines established from thoracic malignancies of diverse his-
tologies. Although the mechanisms have yet to be fully
defined, data presented in this article clearly indicate that
DNMT knockdown represents a novel strategy for the treat-
ment of thoracic neoplasms. These data warrant further
analysis of DNMT expression in aerodigestive tract malig-
nancies and the development of more potent and efficacious
DNMT inhibitors for cancer therapy.
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Dr David R. Jones (Charlottesville, Va). Dr Kassis, you and your
colleagues are to be congratulated for a nice piece of scholarly
work that was well presented. You have shown that the role of
aberrant methylation in thoracic malignancies, particularly with
DNA methyltransferase (DNMT) 1 and DNMT3b, promotes apo-
ptosis in this model system.
I have 3 questions for you. First, most of the trials looking at
antisense oligonucleotides to DNMT require very long treatment
periods. The patients have to receive their infusion over 2 hours or
even longer. They also have to receive multiple cycles of this
therapy, and it is limited to an intravenous formulation. Given the
potential limitations of this, do you believe antisense oligo (ASO)
therapy is even a reasonable treatment strategy, or do you know
perhaps whether there is a pending oral formulation of this type of
treatment?
Dr Kassis. There are now 2 published phase I trials looking at
antisense therapy. As you mentioned, they involved prolonged
infusions, and several months of treatment were necessary before
cancer regressions were noted. What we aimed to do here was to
establish that depletion of DNMT1 or DNMT3b is cytotoxic in
thoracic malignancies. These findings support the development of
small molecular compounds that can be orally administered, which
can efficiently inhibit DNMT expression in cancer cells. Conceiv-
ably, the ASOs used in this study could be formulated for aero-
solized delivery to the respiratory tract or used for local treatment
of dysplastic Barretts epithelium.
Dr Jones. Have you or others looked at combining these
DNMT inhibitors with other kinds of genotoxic stressors, such as
chemotherapy or radiation, to see whether the tumor cell death or
apoptosis could be even further enhanced?
Dr Kassis. To my knowledge, that has not yet been done,
although Dr Schrump and I have discussed combining DNMT
ASOs with deoxyazacytidine. There have now been several stud-
ies demonstrating that DNMT ASOs significantly increase the
deoxyazacytidine-mediated induction of silenced tumor suppressor
genes. So that might be a model that we could pursue in the future.
Dr Jones. Finally, perhaps for me at least, from a mechanistic
standpoint, the most interesting observation of the study is that the
apoptosis that was mediated by the DNMT knockdowns did not
appear to be attributable to genomic demethylation but appeared to
be more likely the result of just a global cellular stress phenome-
non. Can you postulate why this is occurring and why DNMT
depletion appears to induce the growth arrest seen in your study?
Dr Kassis. Thank you for those questions.
Deoxyazacytidine is a potent DNA-demethylating agent that
mediates re-expression of a variety of silenced tumor suppressor
genes. DNMTs have various interactions with methyl-binding
proteins, p21, PCNA, and histone deacetylases. Deoxyazacytidine
covalently traps the DNMTs at the replication fork, promoting
growth arrest and DNA demethylation, with upregulation of genes
that have been silenced by epigenetic mechanisms. In contrast, the
306 The Journal of Thoracic and Cardiovascular Surgery ● FebrASOs inhibit expression of the DNMTs, thereby disrupting the
stoichiometry of critical protein complexes involved in chromatin
remodeling and cell-cycle regulation. We speculate that disruption
of these protein-protein interactions results in profound genotoxic
stress, as indicated by the genes that we saw induced in our
microarray experiments. This genotoxic stress response is not seen
after treatment with deoxyazacytidine.
Dr Chi Ming Wei (Baltimore, Md). I have 3 questions. One,
you tested many different cell lines. Did you find that there is a
different effect for this antisense in different cell lines, or is it a
pretty similar effect?
Dr Kassis. Well, in terms of the growth-inhibitory effect, it was
across the board. In all of the cancer cell lines that we studied, we
saw comparable dose-dependent depletion of the DNMTs. Where
they diverged was in terms of the induction of apoptosis. CALU-6,
A549, 2373, and SKGT5 exhibited significant apoptosis after
DNMT knockdown. In contrast, BIC and H2052 exhibited growth
arrest without significant apoptosis after ASO exposure. This dif-
ference could be related to the kinetics of DNMT knockdown and
the status of the apoptotic machinery in these cells. Experiments
are underway to examine this issue.
Dr Wei. Second, you found that there is no difference in the
p21 gene expression. Did you see the upstream p53 genes?
Dr Kassis. In one cell line, A549, we did see a modest induction
of p21, but we did not study the expression of p53 in this study.
Dr Wei. Third, in the future, do you think it is possible to do
an vivo study, to do this antisense in animal studies?
Dr Kassis. There have been some in vivo studies now looking
at antisense oligonucleotides. As I mentioned, there are actually 2
phase I trials already published, and there is a phase II trial in
patients with oropharyngeal cancer underway in Toronto. There-
fore yes, I think that further in vivo studies are definitely feasible
with this technique.
Dr Wei. Thank you very much.
Dr Ching Tzao (Taipei, Taiwan). I think this is a successful
approach to study the possible mechanism for methylation. Did
you really look at the methylation status and methyltransferase
changes in parallel to see whether it could provide direct evidence
that your findings were indeed involved in methylation? And
another part of this story is histone deacetylation. Are you trying
to find out whether histone deacetylation is related to methylation
of some of the tumor suppressor genes? Is there any cross-talk
between these potential mechanisms?
Dr Kassis. Well, in terms of looking at methylation-specific
PCR to identify the methylation status of some of these promoters,
that was going to be our next step had we identified significant
re-expression of known silenced genes. Therefore no, we did not
do that. And, as you mentioned, there are known interactions
between DNMTs and histone deacetylases. This is an area of
ongoing investigation, but we have not done that yet.Dr Tzao. Thank you.
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TSAppendix E1. Primer-probe sequences for real-time
quantitative RT-PCR
DNMT1
Forward 5=-GTTCTTCCTCCTGGAGAATGTCA-3=
Reverse 5=-GGGCCACGCCGTACTG-3=
Probe 5=-TTGTCTCCTTCAAGCGCTCCATGGTC-3=
DNMT3b
Forward 5=-GACTCGAAGACGCACAGCTG-3=
Reverse 5=-CTCGGTCTTTGCCGTTGTTATAG-3=
Probe 5=-AGCCACCTCTGACTACTGCCCCGC-3=
RASSF1A
Forward 5=-ACG CAC ACG TGG TGC-3=
Reverse 5=-AGT GGC AGG TGA ACT TGC A-3=
Probe 5=-TCG TGC GCA AAG GCC TGC AGT G-3=
p16
Forward 5=-TGCCCAACGCACCGA-3=
Reverse 5=-CGCTGCCCATCATCATGA-3=
Probe 5=-AGTTACGGTCGGAGGCCGATCCA-3=
p21
Forward 5=-CTGGAGACTCTCAGGGTCGAA-3=
Reverse 5=-GGCGTTTGGAGTGGTAGAAATCT-3=
Probe 5=-ACGGCGGCAGACCAGCATGA-3=
TFPI-2
Forward 5=-CAGGAAATAACGCGGAGATCTG-3=
Reverse 5=-ACGGAGAAGTAGGGCCCG-3=
Probe 5=-CTCCTGCCCCTAGACTACGGACCCTG-3=
NY-ESO-1
Forward 5=-TGCTTGAGTTCTACCTCGCCAT-3=
Reverse 5=-GCTCCTGCGGGCCAG-3=
Probe 5=-TTTCGCGACACCCATGGAAGCAG-3=
MAGE-3
Forward 5=-TCCTGTGATCTTCAGCAAAGCTT-3=
Reverse 5=-GGGTCCACTTCCATCAGCTC-3=
Probe 5=-CAGTTCCTTGCAGCTGGTCTTTGGCAT-3=
The Journal of Thoracic aThe primers and probes labeled at the 5= end with the reporter
molecule FAM (6-carboxyfluorocein) and at the 3= end with the
quencher molecule TAMRA (6-carboxytetramethyllodamine)
were purchased from PE Biosystems.
Appendix E2. Microarray analysis of gene
expression in cancer cells after DNMT knockdown
Gene expression profiles in A549 lung cancer cells exposed to
normal media, lipofectin, mismatch oligos, and DNMT1,
DNMT3b, or DNMT1/DNMT3b ASOs were examined by using
long-oligo array techniques. Briefly, after 2-round RNA ampli-
fication, amino-allyl uridine triphosphate–incorporated mi-
croarray probes were synthesized and labeled from 1 g of total
RNA by use of the Ambion aRNA kit. Cy3- and Cy5-labeled
probes were combined and purified in the kit columns and
denatured at 100°C for 1 minute with 10 g of COT-1 DNA
(Invitrogen) and 10 g of poly(A) (Amersham Biosciences).
NCI glass slide microarrays representing 23K genes-features
were prehybridized at 42°C for 2 hours in 5 standard saline
citrate (SSC), 0.1% sodium dodecylsulfate (SDS), and 1%
bovine serum albumin. The arrays were then hybridized with a
probe in 50% formamide, 10 SSC, and 0.2% SDS at 50°C
overnight (10-16 hours). The slides were successively washed
for 2 minutes in 2 SSC, 0.1% SDS, 1 SSC, and 0.2 SSC
and spun dry at 100g for 10 minutes. Arrays were analyzed with
a Genepix 4000B scanner (Axon Instruments) and software
developed at the Center for Information Technology, National
Institute of Health. All arrays were repeated by using reciprocal
fluorescence alteration to establish reproducibility and mini-
mize the effects of labeling bias. A significant expression was
defined as a relative ratio of 3.0 or 0.33 in the experimental
sample relative to reference RNA in 2 reciprocal microarray
analyses.nd Cardiovascular Surgery ● Volume 131, Number 2 306.e1
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DNMT antisense oligo (ASO) transfection by using protocols and reagents described by Beaulieu and colleagues.19
Shown are treatment groups NM (normal media), lipofectin, ASO to DNMT1 (25 and 75 nmol/L), and ASO to DNMT
3b (75 nmol/L). A dose-dependent and specific inhibitor of DNMT1 was observed after transfection with the DNMT1
ASO.306.e2 The Journal of Thoracic and Cardiovascular Surgery ● February 2006
